4P-Pharma’s CSO, Patrice Denèfle, will give a talk on 4P004 : « Accelerating therapeutic innovation for patient through drug repurposing : a use case in Osteoarthritis » at the Drug Discovery Innovation Programme (DDIP) virtual meeting organized by the World BI, on November, 17th 2020, 10:00 a.m CET.
To learn more about 4P-Pharma, our pipeline and our partnerships, please feel free to contact Patrice or Roselina Lam, our Business Developer, via email.
We’re glad to announce that Céline Martin, 4P-Pharma’s R&D Manager will speak during the 10th Drug Discovery Innovation Programme (10th DDIP) organized by the World BI, November 28th-29th 2019, at Barcelona, Spain: “Pharmaceutical Development Through A Rapid Value Creation Business Model”.
A poster on 4P-004 entitled “Protective Effects of Intra-Articular Formulated Liraglutide in Osteoarthritis: Preclinical Studies” (#1973) will be presented during the ACR/ARP Annual Meeting in Atlanta, Georgia November 8 – 13, 2019, by Pr. Francis Berenbaum (Professor of Rheumatology at Sorbonne University, in Paris (France)).
For further information, please click on the following link:
Protective Effects of Intra-Articular Formulated Liraglutide in Osteoarthritis: Preclinical Studies - ACR Meeting Abstracts
Background/Purpose: Osteoarthritis (OA) is a degenerative joint disease affecting millions of individuals worldwide. Its development has been reported to be associated with cartilage degradation and inflammatory responses leading to pain, swelling and reduced function. Liraglutide, a Glucagon-Like-P…
4P-Pharma Team will be attending the upcoming Biofit 2018 conference in Lille December 4-5th. To learn more about possible partnerships, co-development and our pipeline, contact us via the partnering platform or get in touch with our Business Developer Roselina Lam at roselina(at)4p-pharma.com.